8[1]Brisse S, Milatovic D, Fluit A C. Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp using automated ribotyping [J]. J Clin Microbiol, 2000,38 (10): 3636
9[2]Afzal-Shah M, Livermore D M. Worldwide emergence of carbapenem-resistant Acinetobacter spp[J] . J Antimicrob Chemother , 1998,41:576
10[3]Robert E W. Resistant mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria [J]. Clin Infect Dis, 1998,27(Suppll): S93
4Levin AS,Levy CE,Manrique AE,et al.severe nosocomial infection with imipenem-resistance Aecinetobactev baumanniitreated with ampicilin/sulbactam[J].Int J Antimicrob Agented,2003,21(1):58-62.
5NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003,issued August 2003[J].Am J Infect Control,2003,31 (8):481- 498.
6Smolyakov R, Borer R, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter. baumannii bloodstream infection:risk factor and outcome with ampicillin sulbactamtreatmeat [J]. J Hosp Infect,2003,54(1):32-38.
7Clinical Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing[S]. MIO0 S21. CLSI, 2011.
8Vardakas KZ, Matt haiou DK,Falagas ME. Incidence, charac teristics and of patients with severe community ac quired MRSA pneumonia[J]. Eur Respir J,2009,34(5) :1148 1158.
9Thom KA,Johnson JK,I.ee MS, et al. Environmental con- tamination because of muhidrug resistant Acinetobacter bau- mannii surrounding colonized or infected patients[J]. Am J Infect Control,2011,39(9) :711 715.
10Thapa B,Tribuddharat C,Srifuengfung S,et al.High prevalence of bla(OXA)-23 in oligoclonal carbapenem-resistant Acinetobacter baumannii from Siriraj Hospital,Mahidol University,Bangkok,Thailand.[J].Southeast Asian J Trop Med Public Health,2010,41(3):625-635.
